Q-omics provides the consensus-scored LRRC75A profile across patient tissues and cancer cell-line models. LRRC75A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRRC75A is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LRRC75A RNA expression shows 20,766 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where LRRC75A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC75A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC75A survival associations across molecular data types. LRRC75A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC75A RNA expression–survival associations across cancer types. High LRRC75A expression shows unfavorable associations in UVM, MESO, LGG and KIRP, but favorable associations in SCLC and STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRRC75A RNA expression.
This table summarizes LRRC75A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC75A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC75A shows lower tumor expression in COAD and LUAD and higher tumor expression in THCA, KIRC, CHOL and STAD. The COAD box plot shows higher LRRC75A RNA expression in normal versus tumor tissue (log2 FC = −1.423, t-test p < 0.001).
This table shows molecular features associated with LRRC75A in patient tissues and cancer cell lines. In patient samples, LRRC75A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC75A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
